U.S. SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB



(X} QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934

                For the quarterly period ended October 31, 2001

{ }  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR 15 (d)  OF THE  SECURITIES
EXCHANGE ACT OF 1934

     For the transition period from ____________________to________________


                       Commission File Number: 000-27865

                             DISEASE SCIENCES, INC.
        (Exact name of small business issuer as specified in its charter)


              Delaware                               65-1095431
   (State or other jurisdiction of                 (IRS Employer
     Incorporation or organization)               Identification No.)


            20283 State Road 7, Suite 400, Boca Raton, Florida 33498
                    (Address of Principal executive offices)


         Issuer's telephone number, including area code: (561) 487-3655

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.) YES X NO_____

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: 91,669,002 issued and
outstanding at November 29, 2001.



<PAGE>

                             Disease Sciences, Inc.
                      (formerly AuctionAnything.com, Inc.)

                                      INDEX


PART 1.  FINANCIAL INFORMATION

Item 1.  Financial Statements

         Condensed Consolidated Balance Sheet - OCTOBER 31, 2001        2

         Condensed Consolidated Statements of Operations
          (unaudited) for the Three and Nine Months Ended
          October 31, 2001 and 2000 and April 17, 2001 (inception)
          to October 31, 2001                                           3

         Condensed Consolidated Statement of Cash Flows
          (unaudited) for the Nine Months Ended
          October 31, 2001 and 2000 and April 17, 2001 (inception)
          to October 21, 2001                                           4

         Notes to Financial Statements                                 5-7



                                       1
<PAGE>

Item 1. Financial Statements

                             DISEASE SCIENCES, INC.
                      (formerly AuctionAnything.com, Inc.)
                        (A Development Stage Enterprise)

                                October 31, 2001
                      CONDENSED CONSOLIDATED BALANCE SHEET
                                   (UNAUDITED)

                                     ASSETS

Current assets:
     Cash                                                  $       298,904
     Investments                                                     1,500
     Other current assets                                            3,503
                                                              -------------
                                                                   303,907

Equipment, net                                                       1,624
                                                              -------------
                                                                 $ 305,531
                                                              =============

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
     Accounts payable and accrued expenses                 $       141,155
     Notes payable                                                 140,000
                                                             --------------
                                                                   281,155

Stockholders' equity:
     Common stock, $.001 par value; 100,000,000 authorized,
        87,469,002 issued                                           87,469
     Additional paid in capital                                    573,270
     Notes receivable                                             (310,000)
     Accumulated deficit                                          (326,363)
                                                              -------------
        Total stockholders' equity                                  24,376
                                                              -------------
                                                                 $ 305,531
                                                              =============
                       See notes to financial statements
                                       2

<PAGE>

                             DISEASE SCIENCES, INC.
                      (formerly AuctionAnything.com, Inc.)
                        (A Development Stage Enterprise)

                 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
              THREE AND NINE MONTHS ENDED OCTOBER 31, 2001 AND 2000
                  APRIL 17, 2001(INCEPTION) TO OCTOBER 31, 2001
                                   (UNAUDITED)
<TABLE>
<CAPTION>



                                                                                April 17,
                                                                                  2001
                                     Three Months Ended      Nine Months Ended (Inception)
                                          October 31,            October 31,    to October
                                     2001         2000       2001        2000    31, 2001
                                  ---------   ----------  ---------   ---------  ----------
<S>                             <C>            <C>         <C>        <C>       <C>
OPERATING EXPENSES              $   257,921    $    -      $326,363   $   -     $  326,363
                                  ---------   ----------  ---------   ---------  ----------
NET LOSS                        $  (257,921)   $    -     $(326,363)  $   -     $ (326,363)
                                  =========   ==========  =========   =========  ==========
NET LOSS PER WEIGHTED AVERAGE
 SHARES OUTSTANDING
 BASIC AND DILUTED              $    (-)      $    (-)    $  (-)     $   (-)    $     (-)
                                  =========   ==========  =========   =========  ==========
WEIGHTED AVERAGE COMMON SHARES
 OUTSTANDING                      85,187,042  28,790,669  61,416,265  28,520,131 28,520,131
                                  ==========  ==========  ==========  =========  ==========

</TABLE>

                       See notes to financial statements
                                        3


<PAGE>



                             DISEASE SCIENCES, INC.
                      (formerly AuctionAnything.com, Inc.)
                        (A Development Stage Enterprise)
                 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
                   NINE MONTHS ENDED OCTOBER 31, 2001 AND 2000
                  APRIL 17, 2001(INCEPTION) TO OCTOBER 31, 2001
                                   (UNAUDITED)
<TABLE>
<CAPTION>

                                                                                   April 17,
                                                                                2001(Inception)
                                                                                  To October,
                                                      2001             2000        31, 2001
                                                --------------    ------------  ---------------
<S>                                           <C>                <C>           <C>
NET LOSS                                      $      (326,363)   $       -     $     (326,363)
                                                --------------    ------------  ---------------
Adjustments to reconcile net
 loss to net cash provided
 by operating activities:
Depreciation                                              147            -                147
Non cash compensation                                 110,000            -            110,000
Changes in assets and liabilities:
    Increase in other assets                           (3,503)           -             (3,503)
    Increase in accounts payable                       31,155            -             31,155
                                                --------------    ------------  ---------------
NET CASH USED IN OPERATIONS                          (188,564)           -           (188,564)
                                                --------------    ------------- ---------------
CASH FLOWS FROM INVESTING ACTIVITIES
    Purchase of investment                             (1,500)           -             (1,500)
    Purchase of equipment                              (1,771)           -             (1,771)
                                                --------------    ------------- ---------------
NET CASH USED IN INVESTING ACTIVITIES                  (3,271)           -             (3,271)
                                                --------------    ------------- ---------------
CASH FLOWS FROM FINANCING ACTIVITIES
    Notes payable                                     140,000            -            140,000
    Repurchase of treasury stock                     (106,500)           -           (106,500)
    Sale of common stock                              457,239            -            457,239
                                                --------------    ------------- ---------------
NET CASH PROVIDED BY
    FINANCING ACTIVITIES                              490,739            -            490,739
                                                --------------     ------------ ---------------
NET INCREASE IN CASH                                  298,905            -            298,905
                                                --------------     ------------ ---------------
CASH, beginning of period                                -               -               -
                                                --------------     ------------ ---------------
CASH, end of period                           $       298,905 $          -     $      298,905
                                                ==============    ============= ===============
Non-Cash Items:
Common Stock Issued for Notes Receivable      $       310,000 $          -     $         -
                                                ==============    ============= ===============

</TABLE>


                       See notes to financial statements
                                       4

<PAGE>



                              Disease Science, Inc.
                      (formerly AuctionAnything.com, Inc.)

Notes to Condensed Consolidated Financials Statements unaudited

NOTE 1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Financial Statements

The unaudited condensed  consolidated financial statements have been prepared in
conformity  with  generally  accepted  accounting  principles  and  include  all
adjustments  which are,  in the  opinion  of  management,  necessary  for a fair
presentation  of the  results  for  the  interim  periods  presented.  All  such
adjustments are, in the opinion of management, of a normal recurring nature.

The results of  operations  for the three  months and nine months  ended are not
necessarily indicative of those for the full year. In the opinion of management,
the  accompanying   unaudited  financial   statements  contain  all  adjustments
necessary to fairly present the financial position and the results of operations
for the periods indicated.

Certain  information  and footnote  disclosures  normally  included in condensed
consolidated financial statements prepared in accordance with generally accepted
accounting principles have been condensed or omitted. It is suggested that these
condensed  consolidated  financial  statements be read in  conjunction  with the
financial  statements and notes thereto  included in the Company's annual report
on Form 10-KSB for the year ended January 31, 2001.

Organization

Disease  Sciences,   Inc.  (the  "Company"),   a  Delaware  corporation,   is  a
developmental  stage   biopharmaceutical/clinical   diagnostics   company.   The
Company's  long-term  goal is to become a  partially  integrated  pharmaceutical
company with capabilities in research, drug development, clinical investigation,
and  regulatory  affairs.  The  Company is  planning  to employ a broad array of
technologies  to detect,  identify  and  quantify  substances  in blood or other
bodily fluids and tissues. The Company intends to target and develop proprietary
pharmaceutical  compounds  and new  technologies.  Its  primary  goal will be to
develop a  Transmissible  Spongiform  Encephalopathy  (TSE) test,  useful in the
diagnosis  of  TSE  diseases  such  as  scrapie  in  sheep,   Bovine  Spongiform
Encephalopathy  (BSE) in cattle  (commonly  known as mad-cow  disease),  Chronic
Wasting Disease (CWD) in wild deer and elk and  Creutzfeldt-Jakob  Disease (CJD)
in humans. The Company believes these test results may be used in the diagnosis,
detection, evaluation,  monitoring and potential treatment of diseases and other
medical conditions.

On May 23, 2001, the Company completed the acquisition of 100% of the issued and
outstanding  common  stock of Disease  S.I.,  Inc., a Florida  corporation.  The
Company  acquired  100% of the issued and  outstanding  stock of Disease S.I. in
exchange for 60,000,000 shares of common stock.

The  acquisition  of  Disease  S.I.  by has  been  accounted  for  as a  reverse
acquisition under the purchase method for business combinations. The combination
of the two companies is recorded as a recapitalization of Disease S.I., pursuant
to which Disease S.I. is treated as the continuing entity.

Effective July 24, 2001, the Company  completed the sale of North Orlando Sports
Promotions, a wholly owned subsidiary of the Company, and all operating lines of
business  its former  management  group.  Until the sale it was a service  which
established and hosted auction and/or  E-commerce web sites for other businesses
and   organizations   primarily   in   both   the    business-to-business    and
business-to-consumer markets.

NOTE 2.  NOTES PAYABLE

On May 23, 2001 the Company  borrowed a total of $140,000 from two  unaffiliated
third parties. The notes are unsecured, payable upon demand and bear interest at
9% per annum.  For the period  since the date of the notes to October 31,  2001,
the Company has accrued interest payable of $ 5,572 on these notes.

                                       5
<PAGE>


NOTE 3.  TREASURY STOCK

In May 2001, the Company,  repurchased  an aggregate of 8,021,694  shares of its
common stock owned from a former director of the Company, and a company which he
controls,  for an aggregate  purchase price of $106,500.  These shares have been
cancelled and returned to the status of authorized but unissued shares of common
stock.

NOTE 4.  PRIVATE PLACEMENT

The Company  completed a private  placement of 4,700,000  Units (the "Units)" in
August of 2001. Each Unit consisted of one share of common stock and four common
stock  purchase  warrants  designated  Series A, Series B, Series C and Series D
common stock  purchase  warrants  (collectively  the  "Warrants").  The Series A
Warrant  included  in each Unit  entitles  the holder to  purchase  one share of
common stock of the Company at a purchase price of $.30 per share.  The Series B
Warrant  included  in each Unit  entitles  the holder to  purchase  one share of
common stock of the Company at a purchase price of $.60 per share.  The Series C
Warrant  included  in each Unit  entitles  the holder to  purchase  one share of
common stock of the Company at a purchase price of $1.00 per share. The Series D
Warrant  included  in each Unit  entitles  the holder to  purchase  one share of
common  stock of the  Company  at the  purchase  price of $2.00 per  share.  The
Warrants will expire on May 1, 2006.  The Company may call any Warrant series or
all of the  Warrants at a call price of $.001 per  underlying  share  should the
Company's common stock trade at or above $5.00 per share,  based on the reported
closing bid price of the common stock, for 10 consecutive trading days following
15 days prior written notice of the Company's intention to call the Warrants. In
the event the Warrants or Warrant series subject to call have not been exercised
by written notice within such 15-day notice  period,  the Warrants will cease to
exist.

NOTE 5.  RECENT ACCOUNTING PRONOUNCEMENTS

In July 2001,  FASB  issued SFAS No. 141,  Business  Combinations.  SFAS No. 141
requires the purchase method of accounting for business  combinations  initiated
after June 30, 2001 and eliminates the pooling-of-interests  method. The Company
believes that the adoption of SFAS No. 141 will not have a significant impact on
its financial statements.

In July 2001, FASB issued SFAS No. 142,  Goodwill and Other  Intangible  Assets,
which is effective for fiscal years  beginning after December 15, 2001. SFAS No.
142 requires,  among other things, the discontinuance of goodwill  amortization.
In  addition,   the  standard   includes   provisions   upon  adoption  for  the
reclassification  of  certain  existing  recognized   intangibles  as  goodwill,
reassessment   of  the  useful   lives  of  existing   recognized   intangibles,
reclassification  of certain intangibles out of previously reported goodwill and
the testing for  impairment  of existing  goodwill  and other  intangibles.  The
Company is currently assessing but has not yet determined the impact of SFAS No.
142 on its financial position and results of operations.

NOTE 6.  EXERCISE OF STOCK OPTIONS AND NOTES RECEIVABLE

In August 2001 two Directors of the Company  exercised stock options  previously
granted to them under the Company's stock option plan to each acquire  1,000,000
shares of the Company's common stock. As consideration for the exercise price of
$.155  per  share,  each of the  Directors  issued  to the  Company  a one  year
unsecured promissory note in the principal amount of $155,000,  bearing interest
at 5.5% per annum.

                                        6
<PAGE>

NOTE 7.  SUBSEQUENT EVENTS

On November 27, 2001 the Company  acquired  9,050,833 shares of the common stock
of  HealthSpan   Sciences,   Inc.,  a  privately-held   California   corporation
("HealthSpan") in exchange for 4,000,000 shares of its common stock in a private
transaction  exempt  from  registration  under  the  Securities  Act of  1933 in
reliance  on  Section  4(2) of that  act.  The  shares  acquired  in  HealthSpan
represented  approximately  51% of the currently issued and outstanding  capital
stock. A  broker/dealer  which who had previously  been engaged by HealthSpan to
act as its financial advisor received 200,000 of the shares of the Company's our
common  stock  issued  to  HealthSpan  as  compensation   for  its  services  to
HealthSpan.  Bryant Villeponteau,  Ph.D., the Company's Chief Scientific Officer
and a member of its Board of  Directors,  is an officer,  Director and principal
shareholder of HealthSpan.

In  October  2001 the  Company  had  entered  into a  Research  and  Development
Agreement with  HealthSpan  covering the  development  of antioxidant  drugs for
multiple degenerative  diseases. The Research and Development Agreement provides
that it can be  terminated  by the  mutual  consent  of the  parties,  or by the
Company  for cause on 30 days prior  notice if a mutually  agreed  upon group of
scientific  experts  review the research and  development  program and determine
that none of the  potential  analogs  are  likely to be  approved  for  clinical
testing by the Food and Drug  Administration.  If the Research  and  Development
Agreement is terminated under any of these circumstances, HealthSpan will return
3,800,000 shares of the Company's common stock it received in the aforedescribed
transaction  to the Company and the parties will have no further  obligations to
each other.

The Company may also terminate the Research and  Development  Agreement  without
cause on 30 days notice to HealthSpan,  in which event the Company will retain a
number of shares of  HealthSpan's  common  stock  which is the sum of  9,050,883
divided by the number of months remaining in the 24 month term of the agreement,
and the Company will return to HealthSpan the remaining shares which it received
in the Stock Purchase  Agreement.  Contemporaneously,  HealthSpan  will retain a
number of shares of the  Company's  common  stock which is the sum of  3,800,000
divided by the number of months remaining in the 24 month term of the agreement,
and it will return to the Company the remaining  shares which it received in the
Stock Purchase  Agreement less the 200,000 shares paid to the  broker-dealer  as
described above.

Finally,  HealthSpan  can terminate the agreement for cause if the Company fails
to provide  the  funding  described  in the  agreement  or under  certain  other
circumstances  as  described  in the  Research  and  Development  Agreement.  If
HealthSpan  terminates  the  agreement  for cause,  each  company  will return a
proportionate  number of shares of the other company's  common stock acquired in
the Stock Purchase Agreement according to the aforedescribed formula.

                                        7

<PAGE>


Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The following discussion should be read together with the information  contained
in the financial statements and related notes included elsewhere in this report.

Plan of operation

From 1999 until July 2001, we operated a variety of  Internet-related  services.
We  were,   however,   unable  to  generate   positive   cash  flow  from  these
Internet-related businesses. On May 23, 2001, we acquired 100% of the issued and
outstanding  stock of Disease SI,  Inc.  ("Disease  SI"),  a  development  stage
biopharmaceutical/clinical  diagnostics  company,  in  exchange  for  60,000,000
shares of our common stock.  Following  completion of the acquisition of Disease
SI, it  became  apparent  to us that it would be in our best long term  interest
that    the    Internet    operations    be    conducted    apart    from    our
biopharmaceutical/clinical  diagnostics operations.  On July 24, 2001, we sold a
former  director all of the capital  stock of North Orlando  Sports  Promotions,
Inc.,  our  wholly-owned  subsidiary,  in  exchange  for the  assumption  of all
liabilities   related  to  North  Orlando  and  its   operations   estimated  at
approximately $112,000, and which included the forgiveness of $91,500 in accrued
compensation. Included in the sale along with the capital stock of North Orlando
were fixed assets, rights to several domain names and various contractual rights
and obligations.

Following the sale of North Orlando, our long-term goal is to become a partially
integrated   pharmaceutical   company  with   capabilities  in  research,   drug
development,  clinical  investigation,  and regulatory affairs.  Since May 2001,
working  capital to fund our  operations  was  generated  from the  proceeds  of
approximately  $470,000  received  by us  from  the  private  placement  of  our
securities.  During the  balance of fiscal 2001 our plan of  operation  includes
further  research and  development of a TSE screening test, and the extension of
its  technologies  to  several  other  forms of TSE.  We are  planning  clinical
studies,  the costs of which will be borne by us. In furtherance of thereof,  in
August 2001 we agreed to fund a research grant of  approximately  $280,000 for a
two year study on the efficacy of  incineration to inactive  scrapie prions.  In
October 2001 we signed a clinical  trials  agreement  with a company for a urine
diagnostic  test for BSE, CJD and other TSEs.  Finally,  as described  elsewhere
herein,  in November 2001 we acquired 51% of HealthSpan  Sciences,  Inc. and had
previously entered into a research and development agreement with HealthSpan. We
are, at this time however,  unable to project the total costs of these  clinical
studies due to the early stage of our focus in this area.

For the nine months ended October 31, 2001, we reported no revenues. During this
period we reported operating expenses of $326,363,  which includes approximately
$21,000  of  consulting  fees,  approximately  $31,000  in  marketing  expenses,
approximately  $68,000  in  salaries,  and  approximately  $64,000  in legal and
accounting fees, as well as  approximately  $110,000 for accrued but unpaid cash
compensation to our officers and directors.  For the balance of this fiscal year
we anticipate that these operating  expenses will remain  constant,  and we will
begin to incur additional expenses related to the development of our products as
described above.

We do not expect  operating  revenue  in the  foreseeable  future.  We expect to
generate losses  resulting  principally  from costs incurred in conjunction with
our research and development initiatives,  including costs related to scientific
and laboratory personnel, clinical studies and reagents and supplies used in the
development of our technologies, and we expect that the cost of our research and
development  activities will increase substantially as the implementation of our
business plan  continues.  In addition,  as we continue to implement our plan of
operation,   we  expects  general  and   administrative   expenses  to  increase
significantly as we hires additional  personnel and builds our infrastructure to
support future projected growth.  These general and administrative  expenses are
expected  to  consist  primarily  of  non-research  personnel  salaries,  office
expenses and professional  fees. We are unable at this time to project the total
costs of these additional general and administrative expenses.

In October,  we made a  determination  based on our own  enthusiasm and optimism
and,  perhaps,  some  misplaced  confidence  in the  articulated  positions  and
commitments of certain members of the biomedical community.  Following September
11, 2001, people became greatly concerned over a potential  outbreak of Anthrax.
At this time, we found that one of our technologies,  Multi-pulse High Pressure,
could be effective in curing the Anthrax  bacteria.  Our  scientist  believed it
could do so because the process has already killed Bacillus Streptomopholis, the
toughest  Bacillus  strain,  so it made scientific sense that it would also kill
Anthrax.  However,  the  process was not  actually  tested on Anthrax as it is a
bio-terrorism  tool and not readily  available  for  empirical  testing until we
completed the licensing arrangements. Although we believe the statements made in
our press  release on the subject was based on fact and  supported by scientific
literature,  since  we had  not  independently  confirmed  the  efficacy  of the
process,  we agreed  with the SEC to the entry of an Order  wherein we agreed to
cease making any claims without  appropriate  support.  Because of the sensitive
nature of the subject and in our effort to conserve our research dollars,  we do
not  believe it is in our  interest to pursue the  program  notwithstanding  its
potential commercial and societal benefits.

                                        8
<PAGE>



In order to provide sufficient working capital to fund our ongoing operations we
will be required to raise additional  capital to fund these  anticipated  costs.
There are no assurances that we will be able to obtain the additional capital in
which event our future operations would be materially and adversely affected.

Liquidity and Capital Resources

Our working  capital at October 31, 2001 was  $22,752,  and  increase of $47,051
from January 31, 2001. This increase is attributable to  approximately  $457,000
in  working  capital  raised  in  August  2001  in a  private  placement  of our
securities.  Other than our existing working  capital,  we do not have any other
internal sources of working capital.

Since inception, our operating and investing activities have used more cash than
they have generated.  Because of the continued need for  substantial  amounts of
working  capital to fund the growth of the business,  to meet our commitment for
research  funding and to pay our operating  expenses,  we expects to continue to
experience  significant  negative  operating  and  investing  cash flows for the
foreseeable  future. Our existing working capital will not be sufficient to fund
the continued  implementation of our plan of operation during the next 12 months
and to meet our capital  commitments  and  general  operating  expenses.  We are
unable to predict at this time the exact amount of additional working capital we
will require,  however, in order to provide any additional working capital which
we may  require,  we will in all  likelihood  be  required  to raise  additional
capital  through the sale of equity or debt  securities.  We  currently  have no
commitments to provide us with any additional working capital. If we do not have
sufficient  working capital to implement our plan of operation  described above,
it is likely that we will cease operations.

                                        9
<PAGE>



                           Part II - OTHER INFORMATION

Item 1.  Legal Proceedings

         None.

Item 2.  Changes in Securities

         None.

Item 3.  Defaults upon Senior Securities

         None.

Item 4.  Submission of Matters to a Vote of Security Holders

         None.

Item 5.  Other Information

         None.

Item 6.  Exhibits and Reports on Form 8-K

         (b)      Reports on Form 8-K

         On December 4, 2001 we filed a report on Form 8-K pertaining to the
share exchange with HealthSpan Sciences, Inc.

                                       10
<PAGE>



                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                             Disease Sciences, Inc.

                                         By: /s/ Wayne Goldstein
                                                 -------------------
Dated: December 17, 2001                         Dr. Wayne Goldstein,
                                                 President and CEO


                                       11